This finding may have important clinical implications for patients with ER+/PR− HER2-negative tumours since their response to hormone therapies and their prognosis are known to be worse than those of patients with ER+/PR+ tumours [46–48]. This evidence concerns the gene ERBB2 and neoplasm.